{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:38:30Z","timestamp":1792597110314,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,10,21]],"date-time":"2027-10-21T00:00:00Z","timestamp":1824076800000},"content-version":"am","delay-in-days":324,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["P30 DK040561"],"award-info":[{"award-number":["P30 DK040561"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["U24 DK132733"],"award-info":[{"award-number":["U24 DK132733"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["UE5 DK137285"],"award-info":[{"award-number":["UE5 DK137285"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.ecl.2026.07.003","type":"journal-article","created":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:16:36Z","timestamp":1788812196000},"page":"637-648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["GLP-1 Receptor Agonists and Reproductive Health"],"prefix":"10.1016","volume":"55","author":[{"given":"Florence","family":"Porterfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Mulligan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Salim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayemi","family":"Olubowale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima Cody","family":"Stanford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ecl.2026.07.003_bib1","doi-asserted-by":"crossref","first-page":"3113","DOI":"10.1111\/dom.16318","article-title":"Regional trends and disparities in newer GLP1 receptor agonist initiation among real-world adult patients eligible for obesity treatment","volume":"27","author":"Radwan","year":"2025","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.003_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.5694\/mja2.70026","article-title":"Incidence of GLP-1 receptor agonist use by women of reproductive age attending general practices in Australia, 2011-2022: a retrospective open cohort study","volume":"223","author":"Thapaliya","year":"2025","journal-title":"Med J Aust"},{"issue":"23","key":"10.1016\/j.ecl.2026.07.003_bib3","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1001\/jama.2024.7112","article-title":"Dispensing of glucagon-like peptide-1 receptor agonists to adolescents and young adults, 2020-2023","volume":"331","author":"Lee","year":"2024","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.ecl.2026.07.003_bib4","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar","volume":"75","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.003_bib5","doi-asserted-by":"crossref","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","article-title":"Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists","volume":"105","author":"Cena","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.003_bib7","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.2337\/dc09-1203","article-title":"Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes","volume":"33","author":"Rosenstock","year":"2010","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.ecl.2026.07.003_bib8","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1464-5491.2009.02790.x","article-title":"Exenatide efficacy and safety: a systematic review","volume":"26","author":"Norris","year":"2009","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.003_bib12","doi-asserted-by":"crossref","first-page":"906","DOI":"10.4158\/EP.17.6.906","article-title":"Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program","volume":"17","author":"Henry","year":"2011","journal-title":"Endocr Pract"},{"issue":"10","key":"10.1016\/j.ecl.2026.07.003_bib14","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1111\/dom.14465","article-title":"Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11","volume":"23","author":"Bonora","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ecl.2026.07.003_bib15","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1111\/dom.14533","article-title":"Glycaemic efficacy of an expanded dose range of dulaglutide according to baseline glycated haemoglobin (HbA1c) subgroup: post hoc analysis of AWARD-11","volume":"23","author":"Frias","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ecl.2026.07.003_bib17","unstructured":"Wegovy (Semaglutide), FDA label. U.S. Food and Drug Administration\/Center for Drug Evaluation and Research, Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/215256s007lbl.pdf, 2026. Accessed March 16, 2026."},{"issue":"11","key":"10.1016\/j.ecl.2026.07.003_bib18","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.07.003_bib19","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Frias","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.003_bib22","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.07.003_bib23","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jama.2022.0078","article-title":"Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial","volume":"327","author":"Dahl","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.ecl.2026.07.003_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6904-12-8","article-title":"Effect of exenatide on the pharmacokinetics of a combination oral contraceptive in healthy women: an open-label, randomised, crossover trial","volume":"12","author":"Kothare","year":"2012","journal-title":"BMC Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.ecl.2026.07.003_bib25","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1177\/0091270010389471","article-title":"Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol\/levonorgestrel taken as an oral combination contraceptive drug","volume":"51","author":"Jacobsen","year":"2011","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.ecl.2026.07.003_bib26","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s40262-017-0531-7","article-title":"No dose adjustment is recommended for digoxin, warfarin, atorvastatin or a combination oral contraceptive when coadministered with dulaglutide","volume":"56","author":"de la Pena","year":"2017","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.ecl.2026.07.003_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/jcph.443","article-title":"Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol\/levonorgestrel","volume":"55","author":"Kapitza","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.ecl.2026.07.003_bib28","doi-asserted-by":"crossref","first-page":"3509","DOI":"10.2147\/DDDT.S506957","article-title":"A comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1\/GIP receptor agonist","volume":"19","author":"Min","year":"2025","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.ecl.2026.07.003_bib29","unstructured":"Administration USFaD, Clinical pharmacology biopharmaceutics review: dulaglutide 2014, Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2014\/125469Orig1s000ClinPharmR.pdf, 2026. Accessed March 16, 2026."},{"issue":"9","key":"10.1016\/j.ecl.2026.07.003_bib30","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s40262-020-00976-x","article-title":"Effect of oral semaglutide on the pharmacokinetics of levonorgestrel and ethinylestradiol in healthy postmenopausal women and furosemide and rosuvastatin in healthy subjects","volume":"60","author":"Jordy","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib31","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.japh.2023.10.037","article-title":"The impact of tirzepatide and glucagon-like peptide 1 receptor agonists on oral hormonal contraception","volume":"64","author":"Skelley","year":"2024","journal-title":"J Am Pharm Assoc (2003)"},{"issue":"Supplement_1","key":"10.1016\/j.ecl.2026.07.003_bib32","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.2337\/dc26-S009","article-title":"Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026","volume":"49","year":"2026","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"10.1016\/j.ecl.2026.07.003_bib33","article-title":"Pharmacologic treatment of obesity in adults: standards of care in overweight and obesity","volume":"13","year":"2026","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.003_bib34","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1530\/JOE-20-0335","article-title":"Glucagon-like peptide-1 control of GnRH secretion in female sheep","volume":"248","author":"Arbabi","year":"2021","journal-title":"J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.07.003_bib35","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1093\/humupd\/dmz019","article-title":"The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective","volume":"25","author":"Jensterle","year":"2019","journal-title":"Hum Reprod Update"},{"issue":"11","key":"10.1016\/j.ecl.2026.07.003_bib36","doi-asserted-by":"crossref","first-page":"4226","DOI":"10.1210\/en.2014-1978","article-title":"GLP-1 increases preovulatory LH source and the number of mature follicles, as well as synchronizing the onset of puberty in female rats","volume":"156","author":"Outeirino-Iglesias","year":"2015","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.ecl.2026.07.003_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/biom12121736","article-title":"Evidence for Involvement of GIP and GLP-1 receptors and the gut-gonadal axis in regulating female reproductive function in mice","volume":"12","author":"Khan","year":"2022","journal-title":"Biomolecules"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.003_bib38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4093\/dmj.2025.0106","article-title":"Glucagon-like peptide-1 and hypothalamic regulation of satiation: cognitive and neural insights from human and animal studies","volume":"49","author":"Park","year":"2025","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.ecl.2026.07.003_bib39","series-title":"Endotext (Internet)","article-title":"Physiology of GnRH and Gonadotrophin secretion","author":"Marques","year":"2000"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib40","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1111\/dom.70256","article-title":"Hypothalamic RASA1\/Ras\/AKT\/GnRH axis reprogramming mediates GLP-1RA's central rescue of PCOS HPG dysfunction","volume":"28","author":"Yang","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib41","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0198-16.2016","article-title":"GLP-1R signaling directly activates arcuate nucleus kisspeptin action in brain slices but does not rescue luteinizing hormone inhibition in ovariectomized mice during negative energy balance","volume":"4","author":"Heppner","year":"2017","journal-title":"eNeuro"},{"issue":"10545","key":"10.1016\/j.ecl.2026.07.003_bib42","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1016\/S0140-6736(26)00717-8","article-title":"Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process","volume":"407","author":"Teede","year":"2026","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.ecl.2026.07.003_bib43","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25031909","article-title":"Infertility improvement after medical weight loss in women and men: a review of the literature","volume":"25","author":"Pavli","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.003_bib44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.fertnstert.2024.02.038","article-title":"Effectiveness of preconception weight loss interventions on fertility in women: a systematic review and meta-analysis","volume":"122","author":"Caldwell","year":"2024","journal-title":"Fertil Steril"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.rbmo.2017.03.023","article-title":"Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial","volume":"35","author":"Nylander","year":"2017","journal-title":"Reprod Biomed Online"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib46","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1186\/s12902-023-01500-5","article-title":"Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review","volume":"23","author":"Zhou","year":"2023","journal-title":"BMC Endocr Disord"},{"issue":"4","key":"10.1016\/j.ecl.2026.07.003_bib47","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1111\/dom.70452","article-title":"Efficacy of liraglutide on metabolic and reproductive outcomes in women with polycystic ovary syndrome: a systematic review and meta-analysis","volume":"28","author":"Lu","year":"2026","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.003_bib48","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.rbmo.2019.04.017","article-title":"GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis","volume":"39","author":"Han","year":"2019","journal-title":"Reprod Biomed Online"},{"issue":"8","key":"10.1016\/j.ecl.2026.07.003_bib49","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1007\/s43032-023-01222-y","article-title":"The effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-analysis of randomized controlled trials","volume":"30","author":"Ye","year":"2023","journal-title":"Reprod Sci"},{"issue":"1","key":"10.1016\/j.ecl.2026.07.003_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/EJE-18-0175","article-title":"Liraglutide increases IVF pregnancy rates in obese PCOS women with poor response to first-line reproductive treatments: a pilot randomized study","volume":"179","author":"Salamun","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"10.1016\/j.ecl.2026.07.003_bib51","doi-asserted-by":"crossref","first-page":"929","DOI":"10.7326\/ANNALS-25-04820","article-title":"Continuing glucagon-like peptide-1 receptor agonists into the first trimester of pregnancy and pregnancy outcomes\u202f: a target trial emulation study using claims information","volume":"179","author":"Brown","year":"2026","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.ecl.2026.07.003_bib52","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1210\/clinem\/dgaf288","article-title":"Preexisting diabetes and pregnancy: an endocrine society and European Society of Endocrinology Joint clinical practice guideline","volume":"110","author":"Wyckoff","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ecl.2026.07.003_bib53","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.003_bib54","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","article-title":"Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy","volume":"184","author":"Cesta","year":"2024","journal-title":"JAMA Intern Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.07.003_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"key":"10.1016\/j.ecl.2026.07.003_bib56","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes","volume":"246","author":"Hanif","year":"2025","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.ecl.2026.07.003_bib57","doi-asserted-by":"crossref","first-page":"116.e1","DOI":"10.1016\/j.ajog.2025.01.019","article-title":"Preconception glucagon-like peptide-1 receptor agonist use associated with decreased risk of adverse obstetrical outcomes","volume":"233","author":"Imbroane","year":"2025","journal-title":"Am J Obstet Gynecol"},{"issue":"24","key":"10.1016\/j.ecl.2026.07.003_bib58","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1001\/jama.2025.20951","article-title":"Gestational weight gain and pregnancy outcomes after glp-1 receptor agonist discontinuation","volume":"334","author":"Maya","year":"2025","journal-title":"JAMA"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000599?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889852926000599?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:40:58Z","timestamp":1792593658000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889852926000599"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0889852926000599"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.003","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"GLP-1 Receptor Agonists and Reproductive Health","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}